State Of Wisconsin Investment Board Verve Therapeutics, Inc. Transaction History

State Of Wisconsin Investment Board

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.76 - $12.79 $4,555 - $12,240	-957 Reduced 4.04%	22,714 $110,000
Q1 2024 May 14, 2024	SELL	$10.81 - $17.96 $43,077 - $71,570	-3,985 Reduced 14.41%	23,671 $314,000
Q4 2023 Feb 12, 2024	BUY	$8.84 - $18.7 $5,878 - $12,435	665 Added 2.46%	27,656 $385,000
Q3 2023 Nov 14, 2023	BUY	$11.42 - $20.82 $833 - $1,519	73 Added 0.27%	26,991 $357,000
Q2 2023 Aug 14, 2023	SELL	$13.34 - $19.9 $14,620 - $21,810	-1,096 Reduced 3.91%	26,918 $504,000
Q1 2023 May 15, 2023	SELL	$14.3 - $24.01 $42,842 - $71,933	-2,996 Reduced 9.66%	28,014 $403,000
Q4 2022 Feb 14, 2023	SELL	$17.85 - $40.7 $33,807 - $77,085	-1,894 Reduced 5.76%	31,010 $600,000
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $222,836 - $591,522	14,257 Added 76.46%	32,904 $1.13 Million
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $22,870 - $47,568	-2,053 Reduced 9.92%	18,647 $285,000
Q4 2021 Feb 11, 2022	BUY	$31.94 - $54.82 $661,158 - $1.13 Million	20,700 New	20,700 $763,000

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $317M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.